Attendee search 

Immetas discovers and develops novel therapeutics that modulate the innate immune system to treat age-related cancers and inflammatory diseases. The company’s approach is based on emerging evidence that chronic low-grade inflammation is a fundamental process governing aging and age-related diseases, and anchored in clinical evidence to mitigate development risk. Immetas was founded by J. Gene Wang, MD, PhD, a veteran in discovery and translational drug development in immunology/ inflammation and oncology, and David Sinclair, PhD, Professor of Genetics at Harvard Medical School and a leader in the molecular mechanisms of aging. The lead program in the company’s growing pipeline is focused on engineering bispecific antibodies to modulate inflammation in the tumor microenvironment and overcome resistance to the conventional immune checkpoint therapies. Learn more at www.immetas.com

.

VC in Chicago

see company website

Pharma and diagnostics

AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.

PepLib is rethinking peptide drug discovery: a revolutionary platform technology company with a proprietary peptide library, unique screening capabilities, and robust internal drug development programs. PepLib’s novel peptide technology platform uses cyclic peptides to encode and compress half of a billion sequences, including complete peptide libraries up to pentapeptides (ZSenithFive™). PepLib’s platform, powered by Peptide Information Compression Technology (PICT), is capable of high-sensitivity and high-specificity drug mining for a broad spectrum of targets, including membrane-proteins. Intelligently designed, individually isolated and packed peptides in HTS well format support functional assays, including cell-based assay and in vivo assay. PepLib has validated the efficiency of the platform on the well-studied PD-1/PD-L1 model and through their partnerships with multiple pharmaceutical companies and internal development programs in oncology, pain, metabolic disorders, and antimicrobials/antivirals, including COVID. Formed by leading scientists in peptide chemistry and biosynthesis with a combined 75 years of biopharmaceutical R&D experience, PepLib hopes to leverage its innovative platform to advance peptide drug discovery for the global biopharmaceutical community.

We are leaders in therapeutic target discovery and RNA-targeted therapies in Cardiovascular Disease (CVD). Our technology platforms seamlessly integrate synergistically to accelerate development of therapies to treat illnesses where no other treatments have proven effective or ever existed.
We have developed a rich pipeline of therapeutics, including RNAi and NCE's for heart failure, cardiotoxicity, cardiac regeneration and rare cardiometabolic disease.